

Financial news for OGXI dated on 2017-08-01: Companies Holding Shareholder Meetings Today Include CSS Industries, Document Security Systems, Fluidigm, OncoGenex, Prestige Brands, Saputo, SMTc, Steris, Titan Pharma, and Vista Outdoor

Financial news for OGXI dated on 2017-05-15: OncoGenex Pharma Reports Q1 EPS \$(0.11) vs \$(0.12) in Same Qtr. Last Year

Financial news for OGXI dated on 2017-03-01: OncoGenex Pharma, Acieve Lice Science Report Strategic Collaboration with National Institutes of Health for Advancement of Development of Cytisine for Smoking Cessation

Financial news for OGXI dated on 2017-01-05: OncoGenex Shares to Resume Trade at 5 p.m. EST

Financial news for OGXI dated on 2017-01-05: OncoGenex Pharmaceuticals And Achieve Life Science Announce Merger Agreement; Upon Completion, Achieve Equity Holders To Own 75% Of Combined Co. and OncoGenex Shareholders To Own 25% Of Combined Co.

Financial news for OGXI dated on 2017-01-05: OncoGenex Shares Halted News Pending

Financial news for OGXI dated on 2016-11-10: OncoGenex Reports Q3 Loss/Share \$0.12 vs Est Loss/Share \$0.26

Financial news for OGXI dated on 2016-10-28: Oncogenex Will Eliminate ~ 55% Of Its Workforce, Estimates Restructuring Costs ~ \$1.4M

Financial news for OGXI dated on 2016-10-26: Mid-Afternoon Market Update: Crude Oil Down Over 1.5%; NCR Shares Spike Higher

Financial news for OGXI dated on 2016-10-26: 12 Biggest Mid-Day Gainers For Wednesday

Financial news for OGXI dated on 2016-10-26: 18 Stocks Moving In Wednesday's Pre-Market Session

Financial news for OGXI dated on 2016-10-25: OncoGenex Announces Phase 2 Borealis Trial Met Primary Endpoint Of Overall Survival

Financial news for OGXI dated on 2016-10-13: UPDATE: OncoGenex Says Trial Did Not Meet Primary Endpoint of Showing a Statistically Significant Improvement in Overall Survival for Patients Treated with Custirsen in Combo with Docetaxel

Financial news for OGXI dated on 2016-10-13: OncoGenex Reports Results from Phase 3 ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer

Financial news for OGXI dated on 2016-10-13: OncoGenex Pharma Shares Halted News Pending

Financial news for OGXI dated on 2016-08-16: OncoGenex To Resume Trading At 7:30am

Financial news for OGXI dated on 2016-08-16: OncoGenex Reports Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer: Trial Did Not Meet Primary Endpoint

Financial news for OGXI dated on 2016-08-16: OncoGenex Pharma Halted, News Pending

Financial news for OGXI dated on 2016-08-04: OncoGenex Pharmaceuticals Reports Q2 EPS \$(0.23) vs. Est. \$(0.22), Rev. \$2.12M vs. Est. \$1.17M

Financial news for OGXI dated on 2016-06-14: Oncogenex Spikes to High of \$1.17 on Vol

Financial news for OGXI dated on 2016-05-12: OncoGenex Pharma Reports Q1 EPS \$(0.12), Inline, Sales \$2.94M vs \$4.09M Est.

Financial news for OGXI dated on 2016-05-12: OncoGenex Pharmaceuticals Reports Inline Q1 \$(0.12), Sales \$2.94M

Financial news for OGXI dated on 2016-04-26: Oncogenex Shares +30% @\$1.40; Spokesperson Attributes Move in Share Price to Monday's Street.com Article, Momentum; Says No New Milestone Timelines

Financial news for OGXI dated on 2016-03-09: OconGenex Pharmaceuticals Reports Quarter Ended EPS \$(0.06) vs. Est. \$(0.15)

Financial news for OGXI dated on 2016-02-03: Oncogenix Spikes to High of \$0.87 on Volume

Financial news for OGXI dated on 2016-01-21: Here's Why Shares Of Onco Genex Pharma Are Plunging

Financial news for OGXI dated on 2016-01-20: Shares of OncoGenex Pharma Resume, Plunge ~23%

Financial news for OGXI dated on 2016-01-20: OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer

Financial news for OGXI dated on 2016-01-07: 8-K Filings Shows Ionis pharma Filed Lawsuit Against Oncogenex Pharma Over Amended & Restated License Agreement

Financial news for OGXI dated on 2015-12-09: OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial

Financial news for OGXI dated on 2015-12-02: Downside Alert: Here's Exactly Why OncoGenex Pharma Is Having An Awful Start To December

Financial news for OGXI dated on 2015-12-02: Morning Market Losers

Financial news for OGXI dated on 2015-12-02: Benzinga's Top Downgrades

Financial news for OGXI dated on 2015-12-02: Stifel Nicolaus Downgrades OncoGenex Pharmaceuticals to Hold

Financial news for OGXI dated on 2015-12-01: Shares of OncoGenex to Resume Trade at 4:30 p.m. EST

Financial news for OGXI dated on 2015-12-01: UPDATE: OncoGenex Says Expecting Final Results of Phase 3 AFFINITY Trial with Custirsen in 2H'16

Financial news for OGXI dated on 2015-12-01: OncoGenex Announces Phase 3 AFFINITY Trial with Custirsen Continues Following Interim Analyses, Results Expected 2H FY16

Financial news for OGXI dated on 2015-12-01: OncoGenex Shares Halted News Pending

Financial news for OGXI dated on 2015-11-12: OncoGenex Pharmaceuticals Reports Q3 EPS (\$0.16) vs. Est. (\$0.17), Rev. \$6.7M vs. Est. \$7.04M

Financial news for OGXI dated on 2015-10-15: Oncogenix Spike to High on Volume

Financial news for OGXI dated on 2015-10-08: OncoGenex Announces EMA Support for Phase 3 AFFINITY Trial Protocol Amendment

Financial news for OGXI dated on 2015-09-30: OncoGenex Announces Completion of Patient Enrollment in Borealis-2(tm) Clinical Trial Evaluating Apatorsen in Relapsed or Refractory Metastatic Bladder Cancer

Financial news for OGXI dated on 2015-09-28: Morning Market Gainers

Financial news for OGXI dated on 2015-09-28: Benzinga's Top #PreMarket Gainers

Financial news for OGXI dated on 2015-09-28: Onco Genex +18% Premarket Following Announcement of Positive Phase 3 SYNERGY Trial Data

Financial news for OGXI dated on 2015-09-28: OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels in Metastatic Prostate Cancer Patients; Low Levels Correlate with Improved Survival in Those at Increased Risk for Poor Outcomes

Financial news for OGXI dated on 2015-09-23: Morning Market Losers

Financial news for OGXI dated on 2015-09-23: US Stock Futures Rise Ahead Of Manufacturing PMI

Financial news for OGXI dated on 2015-09-23: OncoGenex Pharma Offers Phase 2 Rainier Results Related to Previously Untreated Metastatic Pancreatic Cancer

Financial news for OGXI dated on 2015-08-13: OncoGenex Pharma Reports Q2 Loss of \$0.26/Share, Collaboration Sales \$4.025M

Financial news for OGXI dated on 2015-08-04: An Update On Phase 3 ENSPIRIT Trial - Report on OncoGenex Pharmaceuticals

Financial news for OGXI dated on 2015-07-27: OncoGenex Pharmaceuticals +10% Premarket

Financial news for OGXI dated on 2015-07-14: William Blair Boosts OncoGenex Pharma Target To \$6, Hikes Custirsen Probability To 70%

Financial news for OGXI dated on 2015-07-13: US Stock Futures Signal Higher Start On Wall Street

Financial news for OGXI dated on 2015-07-13: OncoGenex Announces Custirsen Phase 3 "ENSPiRiT" Trial Continues Following Completion of Final Futility Survival Analysis

Financial news for OGXI dated on 2015-06-10: Morning Market Gainers

Financial news for OGXI dated on 2015-06-10: US Stock Futures Signal Higher Start On Wall Street

Financial news for OGXI dated on 2015-06-10: FDA Agrees with OncoGenex' Phase 3 AFFINITY Protocol Amendment

Financial news for OGXI dated on 2015-06-04: Oncogenix Shares Spike Higher; May be Attributed to Comments by Agora Research

Financial news for OGXI dated on 2015-06-01: UPDATE: Oncogenex Pharma Spiking On Data Showing 50% Reduction In Risk Of Death In High Risk Patients When 600MG Of Apatorsen Added With Chemotherapy Combination

Financial news for OGXI dated on 2015-06-01: OncoGenex Reports Data from Borealis-1 Trial Showing Clinical Benefit with Apatorsen in Metastatic Bladder Cancer

Financial news for OGXI dated on 2015-05-30: OncoGenex Announces Positive Data from Phase 3 SYNERGY Trial at ASCO

Financial news for OGXI dated on 2015-05-14: OncoGenex Pharma Reports Q1 Loss \$0.20 Vs Est Loss \$0.34

Financial news for OGXI dated on 2015-04-30: OncoGenex Files Amendment With FDA Regarding Regarding Custirsen Phase 3 "ENSPiRiT" Trial

Financial news for OGXI dated on 2015-04-27: OncoGenex Regains Rights to Custirsen from Teva; Included \$23.2M Payment from TEVA

Financial news for OGXI dated on 2015-01-16: US Stock Futures Slip Ahead Of Goldman Sachs Earnings

Financial news for OGXI dated on 2015-01-16: OncoGenex Says AFFINITY Trial to Continue as Planned Following Completion of Interim Futility Analysis

Financial news for OGXI dated on 2014-12-30: Benzinga's Top #PreMarket Gainers

Financial news for OGXI dated on 2014-12-30: OncoGenex Shares Rise 15% Premarket as Co Announces it Will Regain Rights to Custirsen from Teva

Financial news for OGXI dated on 2014-12-30: US Stock Futures Slip Ahead Of Home Price, Consumer Confidence Data

Financial news for OGXI dated on 2014-12-30: OncoGenex to Regain Rights to Custirsen from Teva

Financial news for OGXI dated on 2014-12-19: OncoGenex Reports Results from Phase 2 BOREALIS-1 Trial of Apatorsen for Metastatic Bladder Cancer

Financial news for OGXI dated on 2014-12-16: US Stock Futures Edge Lower; Crude Oil Drops

Financial news for OGXI dated on 2014-12-16: OncoGenex Announces Completion of Patient Enrollment in the Rainier(tm) Clinical Trial Evaluating Apatorsen in Combination with ABRAXANE(r) plus Gemcitabine in Patients with Metastatic Pancreatic Cancer

Financial news for OGXI dated on 2014-11-17: Events for the Week of Nov. 17-21, 2014

Financial news for OGXI dated on 2014-09-16: OncoGenex Announces Completion of Patient Enrollment in Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-Resistant Prostate Cancer

Financial news for OGXI dated on 2014-08-21: Oncogenex Announces Phase 3 Trials Contiunes As Planned

Financial news for OGXI dated on 2014-08-21: OncoGenex Announces Update on Phase 3 ENSPiRiT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer

Financial news for OGXI dated on 2014-08-07: OncoGenex Pharmaceuticals Inc. Reports Q2 EPS of \$(0.47) Which May Not Compare \$(0.55) Est; Revenue of \$4.90M Which May Not Compare \$9.92M Est

Financial news for OGXI dated on 2014-07-29: Stocks Hitting 52-Week Lows

Financial news for OGXI dated on 2014-07-01: OncoGenex Announces Cedar Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment

Financial news for OGXI dated on 2014-06-26: OncoGenex Pharmaceuticals Prices 5,559,866 Units at \$3.48/Unit

Financial news for OGXI dated on 2014-06-16: 8-K from Oncogenex Pharma Shows VP - Finance Susan Wyrick Has Resigned

Financial news for OGXI dated on 2014-04-30: OncoGenex Pharmaceuticals Inc. Reports Q1 EPS of \$(0.59) vs \$(0.50) Est; Revenue of \$8.64M vs \$8.38M Est

Financial news for OGXI dated on 2014-04-29: RBC Capital Downgrades OncoGenex Pharmaceuticals Inc. to Sector Perform, Lowers PT to \$4.50

Financial news for OGXI dated on 2014-04-29: Stifel Nicolaus Maintains Buy on OncoGenex Pharmaceuticals Inc., Lowers PT to \$9.00

Financial news for OGXI dated on 2014-04-28: Needham Downgrades OncoGenex Pharmaceuticals Inc. to Buy

Financial news for OGXI dated on 2014-04-28: Morning Market Losers

Financial news for OGXI dated on 2014-04-28: Benzinga's Top #PreMarket Losers

Financial news for OGXI dated on 2014-04-28: UPDATE: OncoGenex Shares Fall 56% Following Failed Phase III SYNERGY Trial Results

Financial news for OGXI dated on 2014-04-28: UPDATE: Teva, Oncogenex Offer Top-Line Survival Results of Phase III SYNERGY Trial for Combo with First-Line Docetaxel, Prednisone, Primary End Point Was Not Reached

Financial news for OGXI dated on 2014-04-28: PREVIEW: OncoGenex Pharmaceuticals to Resume Trading at 7:30AM ET

Financial news for OGXI dated on 2014-04-28: Teva, Oncogenex Offer Top-Line Survival Results of Phase III SYNERGY Trial for Combo with First-Line Docetaxel, Prednisone, Primary End Point Was Not Reached

Financial news for OGXI dated on 2014-04-28: OncoGenex Pharmaceuticals Halted; Pending News

Financial news for OGXI dated on 2014-03-11: OncoGenex Pharmaceuticals Inc. Reports Q4 EPS of \$(0.45) vs \$(0.66) Est; Revenue of \$8.60M vs \$10.17M Est

Financial news for OGXI dated on 2014-02-27: UPDATE: CRT Capital Initiates Coverage on OncoGenex

Financial news for OGXI dated on 2014-02-27: CRT Capital Initiates Coverage on OncoGenex Pharmaceuticals Inc. at Buy, Announces \$20.00 PT

Financial news for OGXI dated on 2014-02-27: CRT Capital Initiates Coverage on OncoGenex Pharmaceuticals Inc. at Buy, Announces \$20.00 PT

Financial news for OGXI dated on 2014-02-11: OncoGenex Announces Target Number of Events has been Reached in Phase 3 SYNERGY Trial

Financial news for OGXI dated on 2013-11-19: OncoGenex Announces Phase 3 SYNERGY Trial Evaluating Custirsen is Continuing as Planned

Financial news for OGXI dated on 2013-11-13: Needham Upgrades OncoGenex Pharmaceuticals Inc. to Strong Buy, Maintains \$30.00 PT

Financial news for OGXI dated on 2013-10-28: Needham Upgrades OncoGenex Pharmaceuticals Inc. to Strong Buy

Financial news for OGXI dated on 2013-08-27: US Stock Futures Down Ahead Of Home Prices, Consumer Confidence Data

Financial news for OGXI dated on 2013-08-27: OncoGenex Inititiates Rainier Clinical Trial Evaluating Apatorsen in Combination with ABRAXANE plus Gemcitabine

Financial news for OGXI dated on 2013-08-09: Stifel Nicolaus Maintains Buy on OncoGenex Pharmaceuticals Inc., Lowers PT to \$26.00

Financial news for OGXI dated on 2013-08-08: OncoGenex Pharmaceuticals Inc. Reports Q2 EPS of \$(0.57) vs \$(0.62) Est; Revenue of \$6.30M

Financial news for OGXI dated on 2013-07-16: OncoGenex Completes Patient Enrollment in the Borealis-1 Trial of OGX-427

Financial news for OGXI dated on 2013-05-23: OncoGenex Plans Cedar Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer

Financial news for OGXI dated on 2013-05-02: OncoGenex Pharmaceuticals Inc. Reports Q1 EPS of \$(0.46) vs \$(0.71) Est; Revenue of \$5.08M vs \$5.94M Est

Financial news for OGXI dated on 2013-05-02: OncoGenex Pharmaceuticals Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013

Financial news for OGXI dated on 2013-05-01: OncoGenex to Initiate Rainier Clinical Trial Evaluating OGX-427 with ABRAXANE plus Gemcitabine

Financial news for OGXI dated on 2013-04-09: Stocks Hitting 52-Week Lows

Financial news for OGXI dated on 2013-03-07: OncoGenex Pharma Offers Update on Clinical Development Program

Financial news for OGXI dated on 2013-03-07: OncoGenex Pharmaceuticals Inc. Reports Q4 EPS of \$(0.28) vs \$(0.50) Est; Revenue of \$9.80M vs \$7.46M Est

Financial news for OGXI dated on 2013-02-12: OncoGenex Pharma Outlines Plans for Beginning Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer

Financial news for OGXI dated on 2012-12-19: OncoGenex Announces Initiation of Randomized Phase 2 "PACIFIC" Study of OGX-427 in Combo with Zytiga

Financial news for OGXI dated on 2012-09-27: OncoGenex Announces Initiation Of A Phase 3 Trial For Custirsen In Advanced Non-Small Cell Lung Cancer

Financial news for OGXI dated on 2012-08-07: OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer

Financial news for OGXI dated on 2012-07-11: William Blair Maintains OncoGenex Pharmaceuticals at Outperform, Raises PT from \$19 to \$21

Financial news for OGXI dated on 2012-07-10: OncoGenex Announces Clinical Development Plans for Custirsen in Non-Small Cell Lung Cancer

Financial news for OGXI dated on 2012-05-04: UPDATE: Bloom Burton Maintains Buy Rating, Lowers PT for OncoGenex

Financial news for OGXI dated on 2012-05-04: Bloom Burton & Co. Maintains OncoGenex Pharmaceuticals at Buy, Lowers PT from \$19 to \$18

Financial news for OGXI dated on 2012-03-26: Bloom Burton & Co. Maintains OncoGenex Pharmaceuticals at Buy, Lowers PT from \$24 to \$19

Financial news for OGXI dated on 2012-03-23: OncoGenex Pharmaceuticals Announces Full Exercise of Overallotment Option by Underwriters

Financial news for OGXI dated on 2012-03-16: OncoGenex Pharmaceuticals Prices \$50 Million Public Offering

Financial news for OGXI dated on 2012-03-15: OncoGenex Pharmaceuticals Falls 10% on Offering Announcement

Financial news for OGXI dated on 2012-03-15: OncoGenex Pharmaceuticals Announces Proposed Public Offering of Common Stock

Financial news for OGXI dated on 2012-03-09: UPDATE: Stifel Nicolaus Cuts Target on OncoGenex Pharmaceuticals to \$35

Financial news for OGXI dated on 2012-03-09: UPDATE: Bloom Burton Cuts PT to \$24 on OncoGenex Pharmaceuticals

Financial news for OGXI dated on 2012-03-09: Stifel Nicolaus Maintains OncoGenex Pharmaceuticals at Buy, Lowers PT from \$39 to \$35

Financial news for OGXI dated on 2012-03-09: Bloom Burton & Co. Maintains OncoGenex Pharmaceuticals at Buy, Lowers PT from \$28 to \$24

Financial news for OGXI dated on 2012-03-08: Teva and OncoGenex Announce Updates to

Custirsen Development Program in Advanced Prostate; Second Phase 3 Trial Evaluating Survival Benefit of Custirsen Planned to Initiate in 2012 Cancer

Financial news for OGXI dated on 2012-02-02: Phase 1 Study of OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Shows Early Evidence of Activity in Bladder Cancer

Financial news for OGXI dated on 2011-11-07: Edison Investment Research Publishes Investment Summary on OncoGenex Pharmaceuticals

Financial news for OGXI dated on 2011-10-26: OncoGenex Announces Publication of OGX-427 Pre-Clinical Data in Pancreatic Cancer

Financial news for OGXI dated on 2011-10-20: OncoGenex Pharmaceuticals Initiates an International, Randomized, Phase II Clinical Trial Evaluating OGX-427 in Advanced Bladder Cancer

Financial news for OGXI dated on 2011-09-19: OncoGenex Announces Completion of a Special Protocol Assessment Amendment with the FDA Increasing Patient Eligibility for the Custirsen Phase III Prostate Cancer SATURN Clinical Trial

Financial news for OGXI dated on 2011-08-31: Abingworth LLP Reports 5.0% Passive Stake in OncoGenex

Financial news for OGXI dated on 2011-08-04: OncoGenex Pharma Reports Q2 EPS \$(0.67) vs \$(0.53) Est

Financial news for OGXI dated on 2011-05-19: Teva and OncoGenex to Present Data on Custirsen in Prostate Cancer at the 2011 ASCO Annual Meeting

Financial news for OGXI dated on 2011-04-14: OncoGenex Pharma Announces Key European Patent for OGX-427 (OGXI)

Financial news for OGXI dated on 2011-04-14: OncoGenex Pharmaceuticals Announces Issuance of Key European Patent for OGX-427

Financial news for OGXI dated on 2011-04-06: Teva and OncoGenex Present Preclinical Data on the Activity of its Antisense Compound Custirsen at the American Association of Cancer Research Annual Meeting

Financial news for OGXI dated on 2011-04-04: OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research Annual Meeting

Financial news for OGXI dated on 2010-11-04: OncoGenex Reports Third Quarter Net Loss of \$6.9M

Financial news for OGXI dated on 2010-10-22: OncoGenex Pharmaceuticals, Inc. Closes \$50 Million Offering

Financial news for OGXI dated on 2010-10-20: Benzinga's Volume Movers (HUBG, OGXI, CHKP, ALEX)

Financial news for OGXI dated on 2010-10-19: OncoGenex Pharmaceuticals, Inc. Prices \$50 Million Offering at \$15.75 per Unit

Financial news for OGXI dated on 2010-10-18: OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering

Financial news for OGXI dated on 2010-09-30: Teva and OncoGenex Announce Initiation of Second Phase 3 Trial of Custirsen

Financial news for OGXI dated on 2010-01-06: Benzinga's Top Pre-Market Gainers (ANGO, FDO, OGXI, CLNE, NLST, NICE)

Financial news for OGXI dated on 2009-12-22: Benzinga's Volume Movers (OGXI, ASYS, ENOC, PRGS, AEIS)